Six years ago, this was a thesis. Today, it’s clinical data.
Next week at
#JPM26, we’ll be sharing progress that reflects years of deliberate choices coming together.
Our oral therapy for atopic dermatitis, ENV-294, has generated compelling Phase 1b data showing strong clinical activity and a clean safety profile in one of the largest and most competitive categories in medicine. The signal supports best-in-disease potential and represents exciting clinical proof of the thesis Enveda was built on.
ENV-294 matters not just because it is a strong program, but because it is the output of a system we have been building since day one. A company singularly focused on discovering, developing, and delivering breakthrough medicines with the potential to not just capture, but create markets.
We now have three assets in the clinic:
ENV-294 in atopic dermatitis and asthma, now in Phase 2a with a Jak-like efficacy and a Dupi-like safety profile
ENV-308 for obesity, with the first patient dosed in Phase 1, a “statin for obesity”, engineered for a post-GLP1 world
ENV-6946 for IBD, bringing together clinically validated biology across TNFa, TL1A, IL23, and NLRP3, via a single novel-target delivered in a convenient pill
With additional INDs expected in 2026, Enveda is now a multi-asset clinical-stage company with a highly concentrated set of upcoming catalysts.
Looking ahead over the next several quarters, this foundation provides both momentum and resilience. It positions us to move quickly, take meaningful swings, and continue building a generational company that endures.
We look forward to sharing more next week in San Francisco.
#JPM26 #ENV294 #ENV308 #DrugDiscovery #ClinicalTrials #Biotech #Enveda #LearningFromLife #RevolutionizingImmunology #RevolutionizingObesity